SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Canalis E 1996 Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 81:34413447.
  • 2
    Canalis E 2000 Glucocorticoid-induced osteoporosis. Curr Opin Endocrinol Diabetes 7:320324.
  • 3
    Canalis E, Giustina A 2001 Glucocorticoid-induced osteoporosis: Summary of a workshop. J Clin Endocrinol Metab 86:56815685.
  • 4
    Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M, Stewart PM 2002 Autocrine activation of glucocorticoids in osteoblasts increase with age and glucocorticoid exposure. J Bone Miner Res 17:979986.
  • 5
    Seckl JR, Walker BR 2001 Minireview: 11β -Hydroxysteroid dehydrogenase type 1—a tissue-specific amplifier of glucocorticoid action. Endocrinology 142:13711376.
  • 6
    Diederich S, Quinkler M, Burkhardt P, Grossmann C, Bahr V, Oelkers W 2000 11β hydroxysteroid dehydrogenase isoforms: Tissue distribution and implications for clinical medicine. Eur J Clin Invest 30:2127.
  • 7
    Agarwal AK, Monder C, Eckstein B, White PC 1989 Cloning and expression of rat cDNA encoding corticosteroid 11β dehydrogenase. J Biol Chem 254:1893918943.
  • 8
    Tannin GM, Agarwal AK, Monder C, New MI, White PC 1991 The human gene for 11β hydroxysteroid dehydrogenase. J Biol Chem 266:1665316658.
  • 9
    Jamieson PM, Chapman KE, Edwards CRW, Seckl JR 1995 11β Hydroxysteroid dehydrogenase is an exclusive 11β-reductase in primary cultures of rat hepatocytes: Effect of physicochemical and hormonal manipulations. Endocrinology 136:47544761.
  • 10
    Bujalska I, Shimojo M, Howie A, Stewart PM 1997 Human 11β-hydroxysteroid dehydrogenase: Studies on the stably transfected isoforms and localization of the type 2 isoenzyme within renal tissue. Steroids 62:7782.
  • 11
    Gruber CJ, Tschugguel W, Schneeberger C, Huber J 2002 Production and actions of estrogens. N Engl J Med 346:340352.
  • 12
    Woitge HW, Harrison JR, Ivkosic A, Krozowski Z, Kream B 2001 Cloning and in vitro characterization of α1(I)-collagen 11β hydroxysteroid dehydrogenase type 2 transgenes as models for osteoblast-selective inactivation of natural glucocorticoids. Endocrinology 142:13411348.
  • 13
    Hammami MM, Siiteri PK 1991 Regulation of 11β hydroxysteroid dehydrogenase activity in human skin fibroblasts: Enzymatic modulation of glucocorticoid action. J Clin Endocrinol Metab 73:326334.
  • 14
    Bujalska IJ, Kumar S, Hewison M, Stewart PM 1999 Differentiation of adipose stromal cells: The roles of glucocorticoids and 11β hydroxysteroid dehydrogenase. Endocrinology 140:31883196.
  • 15
    Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CRW, Seckl JR, Mullins JJ 1997 11β Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94:1492414929.
  • 16
    Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, Sheppard MC, Hewison M, Stewart PM 2001 Modulation of 11β hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 16:10371044.
  • 17
    Cooper MS, Walker EA, Bland R, Fraser WD, Hewison M, Stewart PM 2000 Expression and functional consequences of 11β hydroxysteroid dehydrogenase activity in human bone. Bone 27:375381.
  • 18
    Wedel A, Ziegler-Heitbrock HW 1995 The C/EBP family of transcription factors. Immunobiology 193:171185.
  • 19
    Pereira R, Delany A, Canalis, E 2002 Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation. Correlation with CCAAT enhancer binding protein expression. Bone (in press)
  • 20
    Williams LJ, Lyons V, MacLeod I, Rajan V, Darlington GJ, Poli V, Chapman KE 2000 C/EBP regulates hepatic transcription of 11beta-hydroxysteroid dehydrogenase type1. A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways. J Biol Chem 275:3023230239.
  • 21
    Delany AM, Durant D, Canalis E Glucocorticoid suppression of insulin-like growth factor I transcription in osteoblasts. Mol Endocrinol 15:17811789.
  • 22
    Bellows CG, Aubin JE, Heersche JNM 1987 Physiological concentrations of glucocorticoids stimulate formation of bone nodules from isolated rat calvaria cells in vitro. Endocrinology 212:19851992.
  • 23
    Pereira RMR, Delany AM, Canalis E 2001 Cortisol inhibits the differentiation and apoptosis of osteoblasts in culture. Bone 28:484490.
  • 24
    Lee YH, Sauer B, Johnson PF, Gonzalez FJ 1997 Disruption of the C/EBP a gene in adult mouse liver. Mol Cell Biol 17:60146022.
  • 25
    Tanaka T, Yoshida N, Kishimoto T, Akira S 1997 Defective adipocyte differentiation in mice lacking the C/EBPb and/or C/EBPd gene. EMBO J 16:74327443.
  • 26
    Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC 1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J Clin Invest 102:274282.
  • 27
    Delany AM, Gabbitas BY, Canalis E 1995 Cortisol down regulates osteoblast α 1(I) procollagen mRNA by transcriptional and post-transcriptional mechanisms. J Cell Biochem 57:488494.
  • 28
    Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S 1999 Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:43824389.
  • 29
    Rubin J, Biskobing DM, Jadhav L 1998 Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells. Endocrinology 139:10061012.
  • 30
    Zhao W, Byrne MH, Boyce BF, Krane SM 1999 Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice. J Clin Invest 103:517524.
  • 31
    Delany AM, Jeffrey JJ, Rydziel S, Canalis E 1995 Cortisol increases interstitial collagenase expression in osteoblasts by post-transcriptional mechanisms. J Biol Chem 270:2660726612.
  • 32
    Phillipov G, Palermo M, Shackleton CHL 1996 Apparent cortisone reductase deficiency: A unique form of hypercortisolism. J Clin Endocrinol Metab 81:38553860.
  • 33
    Rodin A, Thakkar H, Taylor N, Clayton R 1994 Hyperandrogenism in polycystic ovary syndrome—evidence of dysregulation of 11(Beta)- hydroxysteroid dehydrogenase. N Engl J Med 330:460465.
  • 34
    Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DEW, Johnson O, Walker BR 2001 Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86:14181421.
  • 35
    Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C 2000 Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:9931000.
  • 36
    Carbonare LD, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ 2001 Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 16:97103.
  • 37
    Cohen S, Levy RM, Keller M, Boling E, Enkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA 1999 Risedronate therapy prevents corticosteroid-induced bone loss. A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:23092318.
  • 38
    Reid DM, Hughes RA, Laan RFJM, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer J-P 2000 Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. J Bone Miner Res 15:10061013.
  • 39
    Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Eelmas PD, Malice M-P, Czachur M, Daifotis AG 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292299.
  • 40
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:16271633.